Phone:: +1 877 302 8632
Fax:: +1 888 205 9894 (Toll-free)
E-Mail:: orders@antibodies-online.com

For best experience we recommend to activate Javascript in your browser.

SET Nuclear Oncogene (SET) Peptide

SET Reactivity: Human Host: Rabbit BP

Catalog No. ABIN2764137

Quick Overview for SET Nuclear Oncogene (SET) Peptide (ABIN2764137)

Target

SET/TAF-I (SET) (SET Nuclear Oncogene (SET))

Origin

Human

Source

Rabbit

Application

Blocking Peptide (BP)

SET Nuclear Oncogene (SET) peptide
SET Reactivity: Human, Cow Host: Synthetic BP, Imm

SET Nuclear Oncogene (SET) peptide
SET Reactivity: Mammalian Host: Synthetic BP, IHC, WB

SET Nuclear Oncogene (SET) (N-Term) peptide
SET Reactivity: Human Host: Synthetic BP, IHC, WB, IP

SET Nuclear Oncogene (SET) peptide
SET Reactivity: Human Host: Synthetic BP, BI

Restrictions

For Research Use only
Storage

-20 °C
Target

SET/TAF-I (SET) (SET Nuclear Oncogene (SET))

Background

Human SET was originally identified as part of the SET-CAN fusion gene produced by a somatic translocation event in a patient with acute undifferentiated leukemia. In developing kidney, SET is highly expressed in the zone of nephron morphogenesis. SET has been shown to be a potent and specific inhibitor of protein phosphatase 2A, a family of major serine/threonine phosphatases involved in regulating cell proliferation and differentiation. SET is also involved in the regulation of renal cell proliferation and tumorigenesis. SET mRNA expression is markedly reduced in cells rendered quiescent by serum starvation, contact inhibition, or differentiation. SET protein expression is also much greater in developing rat and human kidney than in fully differentiated, mature kidney. High levels of SET mRNA and SET protein expression arefound in Wilms' tumor, but not in renal cell carcinoma, adult polycystic kidney disease or in transitional cell carcinoma.

You are here: